ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1199

Ultrasound in Clinically Suspect Arthralgia: The Role of Power Doppler to Predict Rheumatoid Arthritis Development

Katerine López1, Isabel Castrejón1, Juan Carlos Nieto1, Javier Rivera1, Teresa González2, Fernando Montero1, Carlos González3, Jose Maria Alvaro-Gracia1 and Juan Molina4, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2H Gregorio Maraon, Madrid, Spain, 3CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 4Hospital General Universitario Gregorio Maran, Madrid, Spain

Meeting: ACR Convergence 2021

Keywords: Clinically Suspect Arthralgia, power Doppler, rheumatoid arthritis, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: It is of great importance to identify patients with clinically suspect arthralgia (CSA) who will develop rheumatoid arthritis (RA) or other inflammatory arthritis (IA) because an early diagnosis and initiation of DMARD therapy of these patients is associated with better long term outcomes. Thus, a prompt detection of inflammation and identification of predictors factors of RA is desirable. Our objective is to determine the usefulness of power Doppler (PD) ultrasound (US) to predict RA development in patients with CSA.

Methods: Retrospective analysis of a US unit cohort over a one-year period. Patients with CSA and no previous diagnosis of IA were included for analysis. All underwent bilateral US examination of hands and/or feet according to the EULAR guidelines. All US examinations were performed by the same rheumatologist, unaware of the physical exam by the referring rheumatologist. The presence of synovitis and tenosynovitis was assessed on a semiquantitative scale (0-3) for gray scale (GS) and PD, respectively. Active US inflammation was defined as synovitis and/or tenosynovitis with PD signal grade ≥1 at any location. RA diagnosis according to clinician criteria 6 months after the US examination was checked. Univariate and multivariate logistic regression models were employed to investigate possible predictive factors of RA development.

Results: A total of 110 CSA patients (80 females, mean age 53.6 years) were included for analysis., Baseline characteristics of the patients with and without development of RA are shown in Table 1. US active inflammation was present in 38 (34.5%) patients (28.2% showed PD synovitis and 19.1% PD tenosynovitis) (Table 2). After 6 months of follow up, 14 (36.8%) of the patients with US active inflammation at baseline evolved toward RA, while none of the patients without PD findings (p< 0.01) had the same evolution. In those patients who evolved to RA, the presence of GS and PD findings at US examination were significantly higher at baseline versus those who did not (100% vs 35.4%, p >0.001 and 100% vs 25%, p >0.001, respectively). Higher ACPA levels, but not RF, were also found to be associated with RA development (462±693.4 vs 30.2±127.6, p< 0.001). In the multivariate analysis, only ACPA (OR 1.004; 95%CI 1-1.007) and the presence of PD US findings at baseline (OR 13.1; CI 1.07-161.04) were found to be independent predictive factors of an evolution towards RA.

Conclusion: US is able to detect features of subclinical inflammation in CSA patients. Both ACPA and the presence of PD findings at baseline US assessment are independent predictors of RA development in CSA patients.

*Multivariate analysis: odds ratio with confidence intervals analysis done if P < 0.2 in univariate analysis.


Disclosures: K. López, None; I. Castrejón, None; J. Nieto, None; J. Rivera, None; T. González, None; F. Montero, None; C. González, None; J. Alvaro-Gracia, None; J. Molina, None.

To cite this abstract in AMA style:

López K, Castrejón I, Nieto J, Rivera J, González T, Montero F, González C, Alvaro-Gracia J, Molina J. Ultrasound in Clinically Suspect Arthralgia: The Role of Power Doppler to Predict Rheumatoid Arthritis Development [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/ultrasound-in-clinically-suspect-arthralgia-the-role-of-power-doppler-to-predict-rheumatoid-arthritis-development/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasound-in-clinically-suspect-arthralgia-the-role-of-power-doppler-to-predict-rheumatoid-arthritis-development/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology